According to The Insight Partners' research, the Europe Prescription Drugs Market was valued at US$ 335.0 Billion in 2024 and is expected to reach US$ 537.6 Billion by 2031, registering a CAGR of 7.0% from 2025 to 2031.
Strategic initiatives by market players and development and adoption of innovative are among the critical factors attributed to driving the Europe prescription drugs market growth.
Various players in the prescription drugs market focus on product approvals, launches, and strategic collaborations to develop effective products required to treat and manage chronic disorders. Subsequently, several recent developments have taken place in the prescription drugs market. A few are mentioned below- In April 2024, ImmunityBio, Inc. received FDA approval for ANKTIVA plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. In October 2022, Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd to add a breakthrough calcitonin gene-related peptide portfolio, including NURTEC ODT, to address the needs of migraine patients worldwide. Ongoing product approvals, launches, and strategic collaborations are driving innovation and expanding treatment options in the prescription drugs market. These developments enhance the management of chronic and complex diseases, improving patient outcomes. Increased focus on generic formulations is helping to improve affordability and accessibility. Overall, these trends are poised to fuel significant market growth soon.
On the contrary, high drug prices and affordability issues hamper the growth of the Europe prescription drugs market.
Europe Prescription Drugs Market Segmentation Analysis:
- By Product Type, the Europe Prescription Drugs Market is segmented into Branded and Generics. The Branded segment is projected to expand at 6.6% CAGR during 2025 - 2031.
- By Drug Type, the Europe Prescription Drugs Market is segmented into Small Molecule and Biologics and Biosimilars. The Small Molecule segment is projected to expand at 4.7% CAGR during 2025 - 2031.
- By Therapeutic Area, the Europe Prescription Drugs Market is segmented into Oncology, Cardiovascular Diseases, Neurological Diseases, Metabolic Diseases, Respiratory Diseases, Immunology, and Others. The Oncology segment is projected to expand at 7.7% CAGR during 2025 - 2031.
- By Route of Administration, the Europe Prescription Drugs Market is segmented into Oral, Injectable, Topical, and Others. The Oral segment is projected to expand at 7.3% CAGR during 2025 - 2031.
- By Distribution Channel, the Europe Prescription Drugs Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment is projected to expand at 7.7% CAGR during 2025 - 2031.
By country, the Europe Prescription Drugs Market is categorized into Germany, the United Kingdom, France, Italy, Spain, Rest of Europe. Germany is projected to expand at 7.4% CAGR during 2025 - 2031.
Key players operating in the Prescription Drugs Market are GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi SA, Johnson & Johnson, AstraZeneca Plc, AbbVie Inc, Eli Lilly and Co, ESTEVE, among others.
- In January 2025, Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., announced that it had entered into a strategic collaboration with Klinge Biopharma GmbH (Klinge) and Formycon AG for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea (aflibercept) in Europe, excluding Italy, and in Israel. This collaboration brought together Teva's extensive commercial expertise in biosimilars with its wide distribution network and strong sales and marketing presence across Europe. It also leverages Formycon's capabilities in developing biosimilar medicines for highly regulated markets. Klinge has obtained exclusive global commercialization rights to FYB203 from Formycon.
- In January 2024, AbbVie launched PRODUODOPA (foslevodopa/foscarbidopa) in the European Union for patients with advanced Parkinson's disease experiencing severe motor fluctuations and involuntary movements. The treatment is intended for cases where current Parkinson's medications have failed to deliver satisfactory results.
Contact Us
Phone: +1-646-491-9876
Email Id: [email protected]